CEL-SCI Corporation, a clinical stage cancer immunotherapy company, has announced the closing of a $5.7 million offering under NYSE American rules. The company sold 1,500,000 shares of its common stock at $3.82 per share. The proceeds from the offering are intended to support the continued development of CEL-SCI's Multikine product, as well as for general corporate purposes and working capital. ThinkEquity acted as the sole placement agent for this offering. The securities were offered under a shelf registration statement filed with the U.S. Securities and Exchange Commission.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。